Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutations

被引：0
|
作者：
Ni, Ting
Huo, Tongxin
Zhang, Yawen
Wang, Jingjing
Liu, Gaoxiang
Shi, Wenting
Gu, Qingyang
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1946
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1946
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mechanisms of acquired resistance to KRAS G12C inhibition in cancer.
    Awad, Mark
    Liu, Shengwu
    Arbour, Kathryn
    Zhu, Viola
    Johnson, Melissa
    Heist, Rebecca
    Patil, Tejas
    Riely, Gregory
    Jacobson, Joseph
    Dilly, Julien
    Yang, Xiaoping
    Persky, Nicole
    Root, David
    Sholl, Lynette
    Lim, Lee
    Garg, Kavita
    Li, Mark
    Engstrom, Lars
    Waters, Laura
    Lawson, J. David
    Olson, Peter
    Christensen, James
    Lito, Piro
    Ou, Sai-Hong Inatius
    Janne, Pasi
    Aguirre, Andrew
    CANCER RESEARCH, 2021, 81 (13)
  • [2] Multiple Mechanisms Underlie the Acquired Resistance to KRAS G12C Inhibition
    Tsai, Y. S.
    Woodcock, M. G.
    Azam, S. H.
    Thorne, L. B.
    Kanchi, K. L.
    Parker, J. S.
    CANCER DISCOVERY, 2022, 12 (03)
  • [3] 针对KRAS G12C的首个抗肿瘤药物——AMG 510
    王灵智
    于芳
    何宇鹏
    李行舟
    临床药物治疗杂志, 2020, 18 (05) : 31 - 34
  • [4] Mechanisms of Resistance to KRAS G12C Inhibitors
    Ambrogio, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S96 - S96
  • [5] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
    Canon, Jude
    Rex, Karen
    Saiki, Anne Y.
    Mohr, Christopher
    Cooke, Keegan
    Bagal, Dhanashri
    Gaida, Kevin
    Holt, Tyler
    Knutson, Charles G.
    Koppada, Neelima
    Lanman, Brian A.
    Werner, Jonathan
    Rapaport, Aaron S.
    San Miguel, Tisha
    Ortiz, Roberto
    Osgood, Tao
    Sun, Ji-Rong
    Zhu, Xiaochun
    McCarter, John D.
    Volak, Laurie P.
    Houk, Brett E.
    Fakih, Marwan G.
    O'Neil, Bert H.
    Price, Timothy J.
    Falchook, Gerald S.
    Desai, Jayesh
    Kuo, James
    Govindan, Ramaswamy
    Hong, David S.
    Ouyang, Wenjun
    Henary, Haby
    Arvedson, Tara
    Cee, Victor J.
    Lipford, J. Russell
    NATURE, 2019, 575 (7781) : 217 - +
  • [6] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
    Jude Canon
    Karen Rex
    Anne Y. Saiki
    Christopher Mohr
    Keegan Cooke
    Dhanashri Bagal
    Kevin Gaida
    Tyler Holt
    Charles G. Knutson
    Neelima Koppada
    Brian A. Lanman
    Jonathan Werner
    Aaron S. Rapaport
    Tisha San Miguel
    Roberto Ortiz
    Tao Osgood
    Ji-Rong Sun
    Xiaochun Zhu
    John D. McCarter
    Laurie P. Volak
    Brett E. Houk
    Marwan G. Fakih
    Bert H. O’Neil
    Timothy J. Price
    Gerald S. Falchook
    Jayesh Desai
    James Kuo
    Ramaswamy Govindan
    David S. Hong
    Wenjun Ouyang
    Haby Henary
    Tara Arvedson
    Victor J. Cee
    J. Russell Lipford
    Nature, 2019, 575 : 217 - 223
  • [7] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [8] Targeting KRAS G12C mutations in colorectal cancer
    Zhao, Ming-He
    Wu, Ai-Wen
    GASTROENTEROLOGY REPORT, 2023, 11
  • [9] CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
    Brazel, Danielle
    Kim, Jennifer
    Ou, Sai-Hong Ignatius
    LUNG CANCER-TARGETS AND THERAPY, 2023, 14 : 31 - 39
  • [10] KRAS G12C Mutations in NSCLC: From Target to Resistance
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Friedlaender, Alex
    CANCERS, 2021, 13 (11)
12345